



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **The Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Hyperplasia**

*Thesis*

*Submitted for Partial Fulfillment of the Master  
Degree in Urology*

*By*

**Mohamed Mahmoud Mohamed Ali Hamouda**  
*M.B.B.CH.*

*Supervised by*

**Prof. Dr. Yousef Mahmoud Kotb**

*Professor of Urology  
Faculty of Medicine, Ain Shams University*

**Dr. Ahmed Mohamed Tawfeek**

*Lecturer of Urology  
Faculty of Medicine, Ain Shams University*

*Ain Shams University*

*Faculty of medicine*

*2020*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the  
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound  
gratitude to **Prof. Dr. Yousef Mahmoud Kotb**,  
Professor of Urology Faculty of Medicine, Ain Shams  
University for his keen guidance, kind supervision, valuable  
advice and continuous encouragement, which made possible  
the completion of this work.*

*I am also delighted to express my deepest gratitude  
and thanks to **Dr. Ahmed Mohamed Tawfeek**,  
Lecturer of Urology Faculty of Medicine, Ain Shams  
University, for his kind care, continuous supervision,  
valuable instructions, constant help and great assistance  
throughout this work.*

*Mohamed Hamouda*

# *List of Contents*

Title	Page No.
List of Tables .....	i
List of Figures .....	iv
List of Abbreviations.....	vii
Introduction .....	1
Aim of the Work.....	4
Review of Literature	
Neuroanatomy of Urinary Bladder .....	5
Bladder Outlet Obstruction .....	13
Assessment of BPH and OAB.....	23
Treatment of BPH and OAB .....	36
Patients and Methods.....	54
Results .....	63
Discussion .....	101
Summary .....	107
Conclusion .....	110
References .....	111
Arabic Summary .....	—

# *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	International prostate symptoms score (IPSS).....	24
<b>Table (2):</b>	Overactive bladder symptom score.....	26
<b>Table (3):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding Age and Prostate size. ....	63
<b>Table (4):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (storage symptoms) before treatment.....	65
<b>Table (5):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (voiding symptoms) before treatment.....	67
<b>Table (6):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding OABSS before treatment .....	69
<b>Table (7):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding urine flowmetry before treatment.....	71
<b>Table (8):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding QoL score before treatment. ....	73
<b>Table (9):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding IPSS (voiding symptoms) .....	74
<b>Table (10):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding IPSS (storage symptoms). ....	76

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (11):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding OABSS. ....	78
<b>Table (12):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding urine flowmetry.....	80
<b>Table (13):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding QOL .....	82
<b>Table (14):</b>	Comparison between patients in the same group (B) before and after treatment with tamsulosin monotherapy regarding IPSS (storage symptoms). ....	83
<b>Table (15):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding IPSS (voiding symptoms). ....	85
<b>Table (16):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding OABSS.....	87
<b>Table (17):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding Urine flowmetry .....	89
<b>Table (18):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding QOL.....	91
<b>Table (19):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (storage symptoms) after treatment. ....	92

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (20):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (voiding symptoms) after treatment .....	94
<b>Table (21):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding OABSS after treatment.....	96
<b>Table (22):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding Urine flowmetry after treatment. ....	98
<b>Table (23):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding QOL after treatment.....	100

# *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Efferent pathways of the lower urinary tract .....	7
<b>Figure (2):</b>	The micturition cycle .....	9
<b>Figure (3):</b>	Prostate anatomy by zone .....	16
<b>Figure (4):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding Age and Prostate size. ....	64
<b>Figure (5):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (storage symptoms) before treatment. ....	66
<b>Figure (6):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (voiding symptoms) before treatment. ....	68
<b>Figure (7):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding OABSS before treatment. ....	70
<b>Figure (8):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding urine flowmetry before treatment. ....	72
<b>Figure (9):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding QoL score before treatment. ....	73
<b>Figure (10):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding IPSS (storage symptoms). ....	75
<b>Figure (11):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding IPSS (voiding symptoms). ....	77

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (12):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding OABSS.....	79
<b>Figure (13):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding urine flowmetry. ....	81
<b>Figure (14):</b>	Comparison between patients in the same group (A) before and after treatment with tamsulosin monotherapy regarding QOL.....	82
<b>Figure (15):</b>	Comparison between patients in the same group (B) before and after treatment with tamsulosin monotherapy regarding IPSS (storage symptoms).....	84
<b>Figure (16):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding IPSS (voiding symptoms).....	86
<b>Figure (17):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding OABSS. ....	88
<b>Figure (18):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding Urine flowmetry. ....	90
<b>Figure (19):</b>	Comparison between patients in the same group (B) before and after treatment with combination treatment regarding QOL. ....	91
<b>Figure (20):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (storage symptoms) after treatment. ....	93

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (21):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding IPSS (voiding symptoms) after treatment. ....	95
<b>Figure (22):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding OABSS after treatment. ....	97
<b>Figure (23):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding Urine flowmetry after treatment.....	99
<b>Figure (24):</b>	Comparison between group(A) monotherapy and group(B) combination therapy regarding QOL after treatment. ....	100

# *List of Abbreviations*

Abb.	Full term
5-ARI .....	5-Alpha reductase inhibitors
5-HMT .....	5-hydroxymethyl
AEs .....	Adverse events
AOB .....	Assignment of Benefits
AUA .....	American Urologic Association
AUR .....	Acute urinary retention
BOO.....	Bladder outlet obstruction
BPE.....	Benign prostatic enlargement
BPH .....	Benign prostatic hyperplasia
BPO .....	Benign prostatic obstruction
CNS .....	Central nervous system
CT .....	Computed tomography
DM .....	Diabetes mellitus
DO.....	Detrusor overactivity
DRE .....	Digital rectal examination
eGFR.....	Estimated glomerular filtration rate
FVC.....	Frequency-volume chart
HTN .....	Hypertension
ICS .....	International Continence Society
IPSS.....	International Prostate Symptom Score
IVU .....	Intravenous urography
LUTS.....	Lower urinary tract symptoms
MR .....	Magnetic resonance
MTOPS.....	Medical Therapy of Prostatic Symptoms
OAB .....	Overactive bladder
OABSS.....	Over active bladder symptoms score
PDE5-I .....	Phosphodiesterase type 5 inhibitors
PPV.....	Positive predictive value
PSA.....	Prostatic specific antigen

## *List of Abbreviations Cont...*

Abb.	Full term
PV .....	Prostate volume
PVR.....	Post-void residual urine
PZ.....	Peripheral zone
Qmax .....	Maximum urinary flow rate
QoL .....	Quality of life
TCAs .....	Tricyclic antidepressants
TURP .....	Transurethral resection of prostate
TZ.....	Transition zone
UF .....	Uroflowmetry
US .....	Ultrasound
USD .....	Urethral stricture disease